# Blinatumomab Maintenance After Allo-HSCT

> **NCT06438796** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 59 (estimated)

## Conditions studied

- High Risk Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT06438796
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06438796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06438796, "Blinatumomab Maintenance After Allo-HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06438796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*